Search results
From Self-sufficiency
- ...(2-ethylthioisonicotinamide, Trecator SC) is an [[antibiotic]] used in the treatment of [[tuberculosis]]. ...=Vannelli TA, Dykman A, Ortiz de Montellano PR |title=The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase |journal=J. Biol.2 KB (278 words) - 16:44, 27 September 2010
- ...name '''Canesten''') is an [[antifungal]] medication commonly used in the treatment of fungal infections of both humans and animals such as [[candidiasis|vagin ==Drug interactions==4 KB (525 words) - 11:13, 20 September 2010
- ...ng|fluːˈkɒnəzoʊl}}) is a [[triazole]] [[antifungal drug]] used in the treatment and prevention of superficial and systemic fungal infections. In a bulk pow ...ess to avoid producing any [[Chirality (chemistry)|chiral]] centers in the drug so that subsequent synthesis and purification would not encounter difficult11 KB (1,533 words) - 16:44, 27 September 2010
- | legal_status = [[Prescription drug|POM]] <small>([[United Kingdom|UK]])</small>, ℞-only <small>(U.S.)</small ...'Grisovin''', a proprietary name of Glaxo Laboratories) is an [[antifungal drug]] that is administered orally. It is used both in animals and in humans, t5 KB (678 words) - 14:58, 19 September 2010
- ...toxicity]] profile, there are currently no injectable formulations of this drug on the US market.<ref>Nystatin on RxList.com http://www.rxlist.com/script/m ...ageal]] ''[[Candida (genus)|Candida]]'' infections usually respond well to treatment with nystatin. ''[[Cryptococcus]]'' is also sensitive to nystatin. In the [7 KB (941 words) - 16:44, 27 September 2010
- ...ungisome, Amphocil, Amphotec) is a [[polyene]] [[antifungal]] [[medication|drug]], often used [[intravenous]]ly for systemic [[fungi|fungal]] [[infection]] Currently the drug is available as plain Amphotericin B, as cholesteryl sulfate complex, as li13 KB (1,785 words) - 16:44, 27 September 2010
- ...[[pyrimidine analogue]], is a synthetic [[Antifungal drug|antimycotic]] [[drug]]. ...synthesized in 1957 but its antifugnal properties discovered in 1964. The drug is dispensed in capsules of 250 mg and 500 mg strength. The injectable form10 KB (1,394 words) - 16:44, 27 September 2010
- ...chemical in photography. KI is a component in some disinfectants and hair treatment hair chemicals. KI is also used as a [[fluorescence quenching]] agent in bi *Saturated solutions of potassium iodide can be an emergency treatment for [[hyperthyroidism]] (so-called [[thyroid storm]]), as high amounts of i23 KB (3,281 words) - 16:44, 27 September 2010
- ...or the treatment of [[herpes simplex virus]] infections, as well as in the treatment of [[herpes zoster|herpes zoster (shingles)]]. ...er and pioneer in antiviral therapy, was the first to successfully use the drug in humans.14 KB (1,878 words) - 16:44, 27 September 2010
- ...DA) on December 18, 1998 and is thus the fifteenth approved antiretroviral drug in the United States. Its patent expired in the United States on 2009-12-2 ...on, in combination with other antiretroviral agents, are indicated for the treatment of HIV-1 infection.8 KB (1,124 words) - 16:44, 27 September 2010
- ...ective against [[HIV]] and used in combination with other [[antiretroviral drug]] therapy as part of highly active antiretroviral therapy (HAART). The related pro-drug of didanosine, 2'3'-dideoxyadenosine (ddA), was initially synthesized by M.9 KB (1,239 words) - 16:44, 27 September 2010
- ...'), is a [[nucleoside]] [[reverse transcriptase inhibitor]] (NRTI) for the treatment of [[HIV]] infection in adults and children. ...proved by the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA) on July 12, 2006 under the brand name '''Atripla'''.5 KB (667 words) - 16:44, 27 September 2010
- ...een used for treatment of chronic [[hepatitis B]] at a lower dose than for treatment of [[HIV]]. It improves the seroconversion of e-antigen positive hepatitis ...tually led to the first oral antiviral agent for the treatment of HBV. The drug was later licensed to the British pharmaceutical company Glaxo by Biochem P9 KB (1,248 words) - 16:44, 27 September 2010
- ...release version for once-a-day dosing in 2001. The fourth [[antiretroviral drug]] on the market, its patent expired in the United States on 2008-06-25. ...dystrophy]], and for this reason it is no longer considered an appropriate treatment for most patients in developed countries.4 KB (574 words) - 16:44, 27 September 2010
- | legal_status = ℞-only <small>(U.S.)</small>, [[Prescription drug|POM]] <small>([[United Kingdom|UK]])</small> ...under the trade name '''Viread''', belongs to a class of [[antiretroviral drug]]s known as nucleotide analogue [[reverse transcriptase inhibitor]]s (nRTIs6 KB (871 words) - 16:45, 27 September 2010
- ...ghly active [[Antiretroviral drug|antiretroviral therapy]] (HAART) for the treatment of a human immunodeficiency virus ([[HIV]]) type 1. ...ides HAART in a single tablet taken once a day. It results in a simplified drug regimen for many patients.10 KB (1,441 words) - 16:45, 27 September 2010
- ...on = [[Kidney|Renal]]: <6% (Parent drug) <br> [[Bile|Biliary]] <5% (Parent drug) As with other [[antiretroviral drug]]s, HIV rapidly develops resistance if nevirapine is used alone, so recomme15 KB (2,090 words) - 16:45, 27 September 2010
- ...pharmacology)|protease inhibitor]] used as a component of [[antiretroviral drug|highly active antiretroviral therapy]] (HAART) to treat [[HIV]] infection a ...y prior antiretroviral drug; using it with dual NRTIs set the standard for treatment of HIV/AIDS and raised the bar on design and introduction of subsequent ant3 KB (320 words) - 15:07, 6 July 2010
- | legal_status = ℞-only <small>(U.S.)</small>, [[Prescription drug|POM]] <small>([[United Kingdom|UK]])</small> '''Lopinavir''' ('''ABT-378''') is an [[Antiretroviral drug|antiretroviral]] of the [[Protease inhibitor (pharmacology)|protease inhibi8 KB (1,109 words) - 16:45, 27 September 2010
- ...ed dose combination (antiretroviral)|fixed dose combination]] drug for the treatment of [[HIV]] infection. It combines [[Gilead Sciences]]'s [[tenofovir]] and [ ...U.S. [[Food and Drug Administration|FDA]] on July 12, 2006. In the UK, the drug cost to the NHS is {{GB£}}620 per month.6 KB (773 words) - 16:45, 27 September 2010